Anti-angiogenic properties of rapamycin on human retinal pericytes in an in vitro model of neovascular AMD via inhibition of the mTOR pathway

Ben Asani1*, Jakob Siedlecki1, Christian Wertheimer2, Raffael Liegl1, Armin Wolf2, Andreas Ohlmann1, Siegfried Priglinger1 and Claudia Priglinger1

Abstract

Purpose: Choroidal neovascularizations (CNV) are partially stabilized through a coverage of pericytes leading to a partial anti-VEGF resistance. Drugs licensed for neovascular AMD (nAMD) do not take this mechanical and growth factor-driven CNV stability into account. The purpose of this work was to see if inhibiting the mammalian target of rapamycin (mTOR) may successfully block angiogenic cellular pathways in primary human retinal pericytes in an in vitro model of nAMD.

Methods: The mTOR inhibitor rapamycin was used to treat human retinal pericytes (HRP) at doses ranging from 0.005 to 15 g/ml. A modified metabolism-based XTT-Assay was used to assess toxicity and anti-proliferative effects. A scratch wound experiment showed the effects on migration. On Cultrex basement membrane gels, the influence of rapamycin on the development of endothelial cell capillary-like structures by human umbilical vein vascular endothelial cells (HUVEC) in the absence and presence of pericytes was investigated.

Results: Rapamycin showed no signs of toxicity within its range of solubility. The drug showed dose dependent anti-proliferative activity and inhibited migration into the scratch wound. Endothelial cell tube formation in a HUVEC monoculture was effectively inhibited at 45%. A co-culture of HUVEC with pericytes on Cultrex induced endothelial tube stabilization but was disrupted by the addition of rapamycin leading to degradation of 94% of the tubes.

Conclusions: Rapamycin allows for an efficient modulation of aspects of angiogenesis in pericytes via mTOR-modulation in vitro. Further studies are needed to elucidate whether rapamycin may have an impact on CNV in nAMD in vivo.

Keywords: Age related macular degeneration, Choroidal neovascularization, VEGF, PDGF, Rapamycin, Sirolimus, mTOR

Introduction

Current treatment strategies for neovascular AMD almost exclusively focus on vascular endothelial growth factor (VEGF) as their pharmacological target [1]. Offering a monotherapy only, all anti-VEGF substances approved nowadays have to be reapplied into the vitreous body regularly, often monthly [2, 3]. Moreover, long-term...
follow-up of patients under anti-VEGF therapy has revealed that in contrast to the visual gains reported after two years, mean visual acuity declines severly after five to seven years [4, 5]. Furthermore, 19.7% - 36.6% had still evidence of active exudation after one year of anti-VEGF therapy [6].

Many additional strategies to improve CNV management beyond anti-VEGF have been proposed [7]. In CNV, anti-VEGF targets endothelial cells, but not cells of the vascular wall [8]. It has frequently been hypothesized that the cells of the vascular wall, namely pericytes, mediate partial anti-VEGF resistance [9–13]. Pericytes are VEGF-independent and rely on platelet-derived growth factor (PDGF) for survival and recruitment to sites of angiogenesis [14–17]. Exploiting this concept, a recent clinical phase 2b trial had demonstrated a beneficial effect of intravitreal anti-PDGF application on nAMD. However, the consecutive large clinical phase 3 trials simultaneously antagonizing VEGF and PDGF finally failed to show superior visual acuity in comparison to anti-VEGF monotherapy [10]. Inclusion criteria were slightly different from the phase 2b trial, which may have caused some bias. Nevertheless, since the phase 3 trials had failed to reach the primary endpoint, the combination therapy as a new option for treatment of nAMD was abandoned.

Thus, there is still an urgent need for alternative approaches targeting angiogenesis beyond VEGF alone as a plethora of in vitro and animal models is providing evidence that the combined inhibition of endothelial cells and pericytes exhibits stronger anti-neovascular properties than sole endothelial cell-targeted anti-VEGF therapy [9, 13, 18], other potential pathways to inhibit pericyte stabilization of CNV under anti-VEGF therapy are of great interest.

The mammalian target of rapamycin (mTOR) signaling pathway is a major regulator of cell growth and proliferation. When deregulated, it is associated with several different diseases including cancer and diabetes [19]. The drug Rapamycin as an inhibitor of the mTOR pathway is nowadays used in the treatment on a number of diseases including but not limited to lymphangioleiomyomatosis or as an immunosuppressant after a kidney transplant [20, 21].

Its function is mainly mediated through binding with the 12-kDa FK506-binding protein (FKBP12) and amplifying its effect as a direct inhibitor of mTOR. This leads to less activity of important upstream regulators such as the serine/threonine kinase S6K1 and PI3-Kinase signaling as an essential mediator of cellular growth and proliferation [19, 22–24].

In in vivo tumor models, inhibition of mTOR was found to reduce angiogenesis and microvascular density [25, 26]. In the eye, inhibition of the mTOR pathway has frequently been described as a new strategy to manage neovascularization in a variety of ocular diseases [27]. The following study was therefore performed to evaluate mTOR-inhibition as an alternative approach to PDGF-antagonism to target angiogenesis in retinal pericytes and endothelial cells in vitro and enhance the current management of CNV in nAMD.

Materials & methods

Rapamycin

Rapamycin powder (Sigma, St. Louis, MO, USA) was dissolved in 100% dimethyl sulfoxide (Sigma, St. Louis, MO, USA). The desired concentration of rapamycin was achieved through dilution in ready-to-use pericyte (Cell Systems, Seattle, USA) or endothelial cell growth medium (PromoCell, Heidelberg, Germany) with a final concentration of 0.1% DMSO for in vitro studies.

Cell culture

Cultures of human retinal pericytes (HRP) were obtained from Cell Systems (Seattle, USA) and cultured according to manufacturer’s instructions in its respective serum-free endothelial growth medium with the included antibiotic (Bac-Off®) and growth factor-mix (CultureBoost™). All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

Cultures of human umbilical vein endothelial cells (HUVEC) were obtained from PromoCell (Heidelberg, Germany) and cultured according to manufacturer’s instructions in its respective serum-free endothelial growth medium with the included growth supplement mix. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

Cellular viability

HUVEC and pericytes were brought to confluence on 12 well Nunc multidishes (Thermo Scientific, Waltham, MA, USA), kept in growth-factor reduced medium for 24h to stop proliferation and treated with vehicle (DMSO; control) or increasing concentrations of rapamycin at 0.005, 0.05, 0.5, 1, 2.5, 5, 7.5, 10, 12.5 and 15 μg/ml, respectively. After 72 hours of treatment, the XTT-Assay was performed as described below. Differences in absorption compared to the untreated control were interpreted as differences in metabolic activity and cell count due to potential toxicity of rapamycin. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

Materials & methods

Rapamycin

Rapamycin powder (Sigma, St. Louis, MO, USA) was dissolved in 100% dimethyl sulfoxide (Sigma, St. Louis, MO, USA). The desired concentration of rapamycin was achieved through dilution in ready-to-use pericyte (Cell Systems, Seattle, USA) or endothelial cell growth medium (PromoCell, Heidelberg, Germany) with a final concentration of 0.1% DMSO for in vitro studies.
**Cellular proliferation**

HUVEC and pericytes were seeded on 12 well Nunc multidishes at about 10-15% of confluence (3x10^5 cells/cm^2). After attachment, cells in their log phase of proliferation were exposed to vehicle or rapamycin as described above. After 72 hours of treatment, an XTT-Assay was performed as described. Differences in absorption compared to the untreated control were interpreted as differences in cell count due to antiproliferative effects of rapamycin. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

**XTT dye reduction assay**

The XTT-Assay was used as previously described by Scudiero [28] and modified for ocular cell culture by Spitzer [29] and Wertheimer [30]. The assay is based on the reduction of the tetrazolium reagent XTT ((2,3-Bis-(2-Methoxy-4-Nitro-5-Sulfophenyl)-2H-Tetrazolium-5-Carboxanilide) into an aqueous-soluble formazan in viable cells, enhanced by the addition of phenazine methosulfate (PMS).

After washing with PBS, 350 μl of XTT reagent, supplemented with 10 μl of 5 mM PMS, were added to each well. After incubation under standard cell culture conditions for one hour, optical density was measured at 450 nm in an ELISA reader (Spectramax 190; Molecular Devices, Sunnyvale, CA, USA). The results are expressed as mean percentage of optic density relative to controls representing 100%. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

**Scratch-induced migration assay**

HRP migration was observed using an in vitro scratch assay as previously described by Liang et al. with a few modifications [31]. Cells were grown on 12 well Nunc multidishes and after reaching confluency, a linear scratch wound was applied to the cell monolayer using a 10 μl pipette tip. The wound was photographed using an inverted phase-contrast microscope with a digital camera (Leica Microsystems GmbH, Solms, Germany), and the exact location of photography was marked on the multidiwth with a felt tip. The cells were then treated with vehicle or increasing rapamycin concentrations of 0.005, 0.05, 0.5 and 5 μg/ml, respectively, and incubated under standard cell culture conditions. After 24 hours, the scratch wounds were photographed again at exactly the same, pre-documented location. Total wound closure (distance between the edge of the wound directly after injury and after 24 h) was assessed with the LAS area measuring tool (Leica, Solms, Germany). The results are expressed as percentage of reduction in wound closure distance with the untreated controls representing 100%. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

**Tube formation: HUVEC monoculture**

Tube formation was observed as described previously [13] on Cultrex® (Trevigen, Gaithersburg, MD, USA), a gel secreted by the murine Engelbreth–Holm–Swarm (EHS)-tumor. The gel, also known as Matrigel, solidifies at 37 °C, forming a basement membrane rich in pro-angiogenic factors on top of which endothelial cells can form tubular complexes. Twenty-four hours before use, Cultrex was thawed on ice in a refrigerator at 4 °C. 50 μl Cultrex per well were placed into a 96-well plate, and solidification was induced in an incubator at 37 °C for 30 minutes. HUVEC were passaged to 1.5 x 10^5 cells/ml and treated with 0.005, 0.05, 0.5 and 5 μg/ml rapamycin. A cell suspension of 100 μl (1.5 x 10^4 cells) was gently added to each well on top of the solidified gel. After incubation at 37°C for 6 h, three images of each well were taken with an inverted phase contrast microscope and a digital camera (Leica, Solms, Germany). Total tube length was evaluated with help of the LAS distance tool (Leica, Solms, Germany) to quantify the length of the vascular system. Results are expressed as percentage of total tube length compared to the untreated control representing 100%. All experiments were conducted on passages 3-7, performed as duplicates and repeated at least three times on different days.

**Tube-formation: HUVEC/HRP co-culture**

After preparing Cultrex as described above, HUVEC were passaged to 1.5 x 10^5 cells/μl and HRP to 7.5 x 10^3 cells/μl. On the first third of the wells, solely 100 μl of HUVEC suspension were added to create HUVEC monocultures. Then, HUVEC and HRP suspension were mixed to seed a HUVEC-HRP coculture on the remaining two thirds of wells as previously described by Stratman et al [32]. After incubation at standard cell culture conditions for 6 hours, three pictures of each well were taken to document the results of tube formation. Immediately afterwards, the co-cultures were treated with concentrations of rapamycin at 0.005, 0.05, 0.5 and 5 μg/ml. After incubation at standard cell culture conditions for another 24 hours, three pictures per well were taken again to document the remains of the tube structures seen after the first 6 hours. Total tube length was evaluated, and results expressed as percentage of the change in total tube length with the control representing 100% as done above for the HUVEC monoculture. All experiments were conducted...
on passages 3-7, performed as duplicates and repeated at least three times on different days.

**Statistical analysis**
Statistical analysis was performed in SPSS 23.0 (SPSS Inc., Chicago, IL, USA). Comparisons between multiple groups were performed by ANOVA with the LSD post hoc test. \( p < 0.05 \) was considered statistically significant with a 95% confidence interval. Graphs were plotted in Microsoft Excel showing the standard deviation.

**Results**

**HRP and HUVEC cell viability**
To exclude any toxic effects of rapamycin on cultured human umbilical vein endothelial cells (HUVEC) and human retinal pericytes (HRP), viability of the cells was investigated after exposure to increasing concentrations of rapamycin as a function of metabolic activity as determined by the XTT-assay. For this purpose, cells were maintained on growth factor depleted conditions. In both, HUVEC and HRP, no statistically significant decrease of metabolic activity could be observed for all tested concentrations ranging from 0.005 to 15 μg/ml (\( p > 0.05 \) for all concentrations, Fig. 1).

**Rapamycin inhibits proliferation of HRP**
When added to cultured HRP in their log phase of proliferative activity rapamycin inhibited proliferation in HRP in a dose-dependent manner at all concentrations tested, ranging from 0.005 up to 15 μg/ml (\( p < 0.05 \) for all concentrations). Dose-dependent effects were observed from 0.005 up to 1 μg/ml, where inhibition of proliferation reached a plateau with a maximal reduction of
proliferative activity by 60%. The half maximal inhibitory concentration (IC_{50}) was 423 ng/ml (Fig. 2).

**Influence of rapamycin on migration of HRP**

The effects of rapamycin on migration of HRP were evaluated in a scratch assay and determined as percentage of the distance covered by the cells after 24 hours compared to the distance covered by the control cells, which was defined as 100% allowing for easy interpretation (distance between the wound gaps at 0h – distance at 24h = 100%). All tested rapamycin concentrations of 0.005, 0.05, 0.5 and 5 μg/ml significantly reduced the mean difference of wound closure by 25.7, 42.0, 56.7 and 76.8 %, respectively (Fig. 2 and Table 1). The inhibitory activity was dose dependant and was observed between 0.005 and 0.5 μg/ml, 0.005 and 5 μg/ml, 0.05 μg/ml and 5 μg/ml as well as 0.5 and 5 μg/ml (Table 2).

**Effect of rapamycin on tube formation in a HUVEC monoculture**

On regular Cultrex® all tested concentrations of rapamycin (0.005, 0.05, 0.5 and 5 μg/ml) led to a statistically significant decrease in the tube length by 26.0, 36.4, 40.9 and 45.1 %, respectively, relative to the untreated control (Fig. 3; Table 3). A dose dependent effect was observed from 0.005 to 5 μg/ml (Rapa 0.005 – Rapa 0.5: \(p<0.0001; \) MD 15.0; 95 % CI: 7.0 – 31.4).

**Rapamycin leads to a disruption of tube stability in a HRP and HUVEC co-culture**

In vivo, endothelial tubes are sheathed and thereby stabilized by pericytes. In order to create a comparable condition in vitro, we established a co-culture of HUVEC and HRP.

Addition of HRP to the HUVEC monoculture led to a statistically significant increase in tube stability. The HUVEC monoculture showed 67.7 % more tube degradation after 30 hours when compared to the co-culture of HUVEC and HRP (HUVEC/HRP – HUVEC: \(p<0.0001; \) MD 67.7; 95 % CI: 52.9 – 82.6). All rapamycin concentrations tested (0.005, 0.05, 0.5 and 5 μg/ml) led to a statistically significant decrease of total tube length by 45.1, 78.9, 80.0 and 94.0 %, respectively, relative to the untreated co-culture control (Fig. 3, Table 4). A dose dependent effect was observed from 0.005 to 5 μg/ml (Rapa 0.005 – Rapa 0.5: \(p<0.0001; \) MD 49.0; 95 % CI: 34.1 – 63.8).

**Discussion**

The pharmacological inhibition of VEGF has revolutionized the treatment of nAMD. However, many patient needs, mainly the long-term preservation of visual acuity and an alleviation of the current treatment burden, are still unmet [2, 4, 5]. These present limitations of anti-VEGF are largely attributable to insufficient CNV management, and the fact that cells of the vascular wall, mainly pericytes, and their promotion of vessel maturation and stabilization are unaffected by anti-VEGF as nowadays standard of care [9–13].

The goal of the present study was to examine the anti-angiogenic effects of rapamycin in an in vitro model of nAMD. Using well established models of cellular mechanisms involved in angiogenesis [12, 13, 31], we were able to show that the mTOR inhibitor rapamycin successfully suppresses endothelial cell tube formation comparable to anti-VEGF agents.

This is in line with previous findings showing that rapamycin can interfere with VEGF signaling [33], mainly interacting with VEGF-A driven early angiogenesis by modulation of the S6 tyrosine-kinase [34, 35]. Furthermore, as shown in lymphatic endothelial cells tube formation is reduced by rapamycin via downregulation of VEGF receptor 3 [36]. In our hands, rapamycin led to a significant dose-dependent reduction of total tube length in endothelial cell monocultures. Although not investigated in this work, this suggests that rapamycin might also interfere with VEGF receptor 2 which has been shown to be the main mediator of tubulogenesis in blood endothelial cells [37, 38]. This subject clearly awaits further investigation.
Liu et al. previously have shown that inhibiting mTOR can reduce proliferation and migration not only in endothelial cells, but also in pericytes in breast cancer models in mice [25]. Our study provides further evidence that rapamycin can also be used to modulate retinal pericyte growth in CNV angiogenesis by targeting the pathological vessel maturation and therefore add to the effect of anti-VEGF on the endothelial cell. Mechanistically, pericytes are thought to mediate a partial anti-VEGF resistance by conferring vascular stabilization via physical contact, VEGF and the Ang1/Tie2 system [16, 39, 40]. In our study, rapamycin dose-dependently reduced pericyte proliferation and migration and interfered with the pericyte stabilization of endothelial tubes, inducing vascular regression even in endothelial cell tube structures which had undergone pericyte coverage in a cellular co-culture. However, it is important to note that these are in vitro results and that other protocols on performing co-culture assays exist. Stahl et al. for example used two different layers of collagen gels for each cell line to investigate the

**Table 3** Effects of rapamycin on HUVEC tube formation compared to the untreated control

| P Value | Mean Deviation | 95% CI  |
|---------|----------------|---------|
| Co – rapa 0.005 | 0.001 | 26.0 | 13.8 – 36.2 |
| Co – rapa 0.05 | <0.0001 | 36.4 | 24.2 – 48.6 |
| Co – rapa 0.5 | <0.0001 | 40.9 | 28.7 – 53.1 |
| Co – rapa 5 | <0.0001 | 44.1 | 33.0 – 57.3 |

**Table 4** Effects of rapamycin on tube stability in a co-culture tube formation

| P Value | Mean Deviation | 95% CI  |
|---------|----------------|---------|
| Co – rapa 0.005 | 0.001 | 26.0 | 13.8 – 36.2 |
| Co – rapa 0.05 | <0.0001 | 36.4 | 24.2 – 48.6 |
| Co – rapa 0.5 | <0.0001 | 40.9 | 28.7 – 53.1 |
| Co – rapa 5 | <0.0001 | 44.1 | 79.1 – 108.9 |

Fig. 3 Effects of Rapamycin on tube formation in a HUVEC monoculture (A) compared to a HUVEC/HRP co-culture (B). Tube formation after 6 hours is significantly reduced under Rapamycin compared to the untreated control leading to a decrease down to 74.0%, 63.6%, 59.1% and 54.9% respectively (Co – Rapa 0.005: p<0.001; MD: 26.0; 95 % CI: 13.8 – 38.2; Co – Rapa 0.05: p<0.0001; MD 36.4; 95 % CI: 24.2 – 48.6; Co – Rapa 0.5: p<0.0001; MD 40.9; 95 % CI: 28.7 – 53.1; Co – Rapa 5: p<0.0001; MD 45.1; 95 % CI: 33.0 – 57.3). However, HUVEC monoculture tubes destabilize also without treatment after 30 hours while still being steady after the same time frame by adding pericytes and thus creating a co-culture comparable to the in vivo condition. B: Adding Rapamycin to the co culture tubes seems to disrupt endothelial tube stabilization (Co – Rapa 0.005: p<0.0001; MD: 45.1; 95 % CI: 30.2 – 59.9; Co – Rapa 0.05: p<0.0001; MD 78.9; 95 % CI: 64.1 – 93.8; Co – Rapa 0.5: p<0.0001; MD 80.0; 95 % CI: 65.1 – 94.8; Co – Rapa 5: p<0.0001; MD 94.0; 95 % CI: 79.1-108.9)
et al. have demonstrated that pathological angiogenesis also modulates fibrotic responses of CNV generated in this context, pericyte inhibition using rapamycin might be a potential therapy target for subretinal fibrosis [46]. In the expressions of fibrogenic molecules, making them higher vascular permeability might be forced back into VEGF-dependency by rapamycin-induced pericyte ablation.

However, these findings reflect the wide efficacy of rapamycin on pericytes at two crucial time points in vessel maturation. First, as shown by Benjamin et al. [42], pericyte recruitment and vessel coverage lag behind primary endothelial cell driven angiogenesis, opening a plasticity window for vascular remodeling. By the addition of rapamycin to conventional anti-VEGF therapy, pericyte migration and proliferation to sites of nascent CNV might be limited, thus reducing the amount of pericyte coverage of maturing endothelial tubes. Secondly, already matured, pericyte covered endothelial tubes were significantly more vulnerable when rapamycin was added to the coculture. In a clinical context, this might allow for CNV regression if a combination therapy with conventional anti-VEGF inhibitors is applied [16]. In nAMD, VEGF-independent parts of CNV due to pericyte coverage might be forced back into VEGF-dependency by rapamycin-induced pericyte ablation.

From a clinical perspective, an induction of vessel regression is of high importance. Studies monitoring anti-VEGF treatment with optical coherence tomography angiography (OCT-A) have shown that CNVs react to the therapy by decreases in size and perfusion, but show persistence in their voluminous large vessel trunks and regrow upon sinking anti-VEGF levels [43, 44]. Phung et al. have demonstrated that pathological angiogenesis is induced and sustained by Akt activation, causing increased blood vessel size and ongoing edema due to higher vascular permeability [45]. Apart from its effects on the pericyte, rapamycin was suggested to reverse these changes by working as an inhibitor of endothelial Akt signaling, inducing vessel normalization of physiological segments [45]. Moreover, mature CNV segments forced into pericyte ablation by rapamycin might show delayed regrowth, and thus prolonged treatment intervals.

In a previous study we have shown that pericytes may contribute to subretinal fibrosis in nAMD [12]. This was recently confirmed by findings showing that pericytes activated by laser photocoagulation infiltrated the subretinal space in mice models, increasing the expressions of fibrogenic molecules, making them a potential therapy target for subretinal fibrosis [46]. In this context, pericyte inhibition using rapamycin might also modulate fibrotic responses of CNV generated in the macula, a frequent cause of serious vision loss in nAMD [47].

In conclusion, our in vitro data spurs further in vitro and in vivo studies on rapamycin as an antiangiogenic treatment for nAMD targeting the pericyte. As shown by recent phase 3 trials of rapamycin for the treatment of uveitis [48], intravitreal delivery of this promising substance can already be considered as safe. We believe that further investigation of this pathway, especially if the substance is to be delivered as a monotherapy or in combination with other anti-VEGF agents, could be a key in advancing the treatment options for neovascular AMD.

Acknowledgments
Not applicable.

Authors’ contributions
B.A.: acquisition of data, conducting the experiments, drafting of manuscript, review, and synthesis of literature. J.S.: conceptualization of the manuscript and review and synthesis of the literature, analysis and interpretation of data, critical review and revision of the manuscript. C.W., R.L., A.W. and S.P.: critical review and revision of the manuscript, analysis and interpretation of data. A.O.: critical review and revision of the manuscript, analysis and interpretation of data, consulting for correct execution of the experiments. C.P.: conceptualization of the manuscript, critical review and revision of the manuscript, conception and design of the work/project, analysis and interpretation of data, conducting the experiments. All authors contributed to the article and approved the submitted version.

Funding
Open Access funding enabled and organized by Projekt DEAL.

Availability of data and materials
The datasets used and/or analysed during the current study are available from the corresponding author on reasonable request due to ongoing further analysis.

Declarations
Ethics approval and consent to participate
Not applicable.

Consent for publication
Not applicable.

Competing interests
Christian Wertheimer, Raffael Liegl, Andreas Ohlman and Claudia Priglinger declare that they have no financial or competing interests. Ben Asani has received speaker fees from Novartis Pharma GmbH. Jakob Siedlecki receives speaker honoraria and travel reimbursement from Carl Zeiss Meditec AG, Novartis Pharma GmbH, Bayer AG, Pharm-Allergan GmbH, Oculentis; OSD Medical GmbH, Consultant: Bayer AG, Novartis Pharma GmbH, Pharm-Allergan GmbH. Travel reimbursement: Oertli AG. Armin Wolf receives fees for lectures/consulting or research funding from Novartis Pharma GmbH; Bayer Healthcare AG, Alimera; Allergan, Oertli Instrumente AG, Roche and Appellis. Siegfried Priglinger receives speaker and consultant honoraria from and has served on advisory boards for Abbott, Alcon, Gedeon, Oculus, Schwind, STAAR, TearLab, Thieme Compliance, Ziemer, Zeiss and research funding from Abbott, Alcon, Hoya, Oculentis, Oculus, Schwind and Zeiss.

Author details
1 Department of Ophthalmology, Ludwig-Maximilians-University, Mathildenhöhestrasse 8, 80336 Munich, Germany. 2 Department of Ophthalmology, University Clinic Ulm, Ulm, Germany.
References

1. Falavarjani KG, Sadda SR. Hot Topics in Pharmacotherapy for Neovascular Age-Related Macular Degeneration. Curr Pharmaceut Design. 2017;23(4):335–41.

2. Curtis LH, Hammill BG, Qualls LG, DiMartino LD, Wang F, Schulman KA, et al. Treatment patterns for neovascular age-related macular degeneration: analysis of 284,380 Medicare beneficiaries. Am J Ophthalmol. 2012;153(6):1116–1124.e1111.

3. Semeraro F, Morescalchi F, Duse S, Gambicorni E, Cancarini A, Costagliola C. Pharmacokinetic and Pharmacodynamic Properties of Anti-VEGF Drugs After Intravitreal Injection. Curr Drug Metab. 2015;16(7):572–84.

4. Maguire MG, Martin DF, Ying GS, Jaiffie JG, Daniel E, Grunwald JE, et al. Five-year outcomes with anti-vascular endothelial growth factor treatment of neovascular age-related macular degeneration: the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2016;123(8):1751–61.

5. Rofagha S, Bhishitkul RB, Boyer DS, Sadda SR, Zhang K. Seven-year outcomes in ranibizumab-treated patients in ANCHOR, MARINA, and HORIZON: a multicenter cohort study (SEVEN-UP). Ophthalmology. 2013;120(1):2292–9.

6. Heier JS, Brown DM, Chong V, Korobelnik JF, Kaiser PK, Nguyen QT, et al. Intravitreal aflibercept (VEGF trap-eye) in wet age-related macular degeneration. Ophthalmology. 2012;119(12):2537–48.

7. Ehrenberg M, Benny O. Evolving multidimensional pharmacological approaches to CNV therapy in AMD. Curr Eye Res. 2018;43(2):147–54.

8. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669–76.

9. Erber R, Schachar RA, et al. Axitinib inhibits retinal and choroidal neovascularization in a transgenic mouse model of ErbB2-dependent human breast cancer. Cancer Res. 2005;65(12):5325–36.

10. Saiko K, Matsumoto S, Yasiu H, Devasahayam N, Subramanian S, Munasinghe JP, et al. Longitudinal imaging studies of tumor microenvironment in mice treated with the mTOR inhibitor rapamycin. PLoS One. 2012;7(11):e49456.

11. Liedl R, Koenig S, Siedlecki J, Hantogloou C, Kampik A, Kernt M. Tensirsirolimus inhibits proliferation and migration in retinal pigment epithelial and endothelial cells via mTOR inhibition and decreases VEGF and PDGF expression. PLoS one. 2014;9(2):e88203.

12. Scudiero DA, Shoemaker RH, Paull KD, Monks A, Tierney S, Nofziger TH, et al. Evaluation of a soluble tetrazolium/formazan assay for cell growth and drug sensitivity in culture using human and other tumor cell lines. Cancer Res. 1988;48(17):4827–33.

13. Spitzer MS, Wallenfels-Thilo B, Spiro RR, Pfeiffer H, Enke-Schwarz J, et al. Antiproliferative and cytotoxic properties of bevacizumab on different ocular cells. Br J Ophthalmol. 2006;90(10):1316–21.

14. Wertheimer C, Kassumeh S, Pijlman JP, Nilmayer O, Braun C, Priglinger S, et al. The intraocular lens as a drug delivery device: In vitro screening of pharmacologic substances for the prophylaxis of posterior capsule opacification. Invest Ophthalmol Vis Sci. 2017;58(14):6408–18.

15. Liang CC, Park AY, Guan JL. In vitro scratch assay: a convenient and inexpensive method for analysis of cell migration in vitro. Nat Protocols. 2007;2(2):329–33.

16. Stratman AN, Malotte KM, Mahan RD, Davis MI, Davis GE. Pericyte recruitment during vasculogenic tube assembly stimulates endothelial basement membrane matrix formation. Blood. 2009;114(24):S01–101.

17. Riesther O, Zingg D, Hummerjohann J, Bodis S, Pruscy M. Degradation of PKB/Akt protein by inhibition of the VEGF receptor/mTOR pathway in endothelial cells. Oncogene. 2004;23(26):4624–35.

18. Kim DD, Kleinman DM, Kanetaka T, Gerritsen ME, Nivaggioli T, Weber D, et al. Rapamycin inhibits VEGF-induced microvascular hyperpermeability in vivo. Microcirculation. 2010;17(2):128–36.

19. Xue Q, Nagy JA, Manseau EJ, Phung TL, Dvorak HF, Benjamin LE. Rapamycin inhibition of the Akt/mTOR pathway blocks select stages of VEGF-A164-driven angiogenesis, in part by blocking S6Kinase. Arteriosclerosis Thrombosis Vasc Biol. 2009;29(8):1172–8.

20. Luo Y, Liu L, Rogers D, Su W, Odaka Y, Zhou H, et al. Rapamycin inhibits lymphatic endothelial cell tube formation by downregulating vascular endothelial growth factor receptor 3 protein expression. Neoplasia. 2012;14(3):228–37.
41. Stahl A, Paschek L, Martin G, Gross NJ, Feltgen N, Hansen LL, et al. Rapamycin reduces VEGF expression in retinal pigment epithelium (RPE) and inhibits RPE-induced sprouting angiogenesis in vitro. FEBS Lett. 2008;582(20):3097–102.

42. Benjamin LE, Hemo I, Keshet E. A plasticity window for blood vessel remodelling is defined by pericyte coverage of the preformed endothelial network and is regulated by PDGF-B and VEGF. Development (Cambridge, England). 1998;125(9):1591–8.

43. Huang D, Jia Y, Rispoli M, Tan O, Lumbroso B. Optical coherence tomography angiography of time course of choroidal neovascularization in response to anti-angiogenic treatment. Retina (Philadelphia, Pa). 2015;35(11):2260–4.

44. Muakkassa NW, Chin AT, de Carlo T, Klein KA, Baumal CR, Witkin AJ, et al. Characterizing the effect of anti-vascular endothelial growth factor therapy on treatment-naive choroidal neovascularization using optical coherence tomography angiography. Retina (Philadelphia, Pa). 2015;35(11):2252–9.

45. Phung TL, Ziv K, Dabydeen D, Eyiah-Mensah G, Riveros M, Perruzzi C, et al. Pathological angiogenesis is induced by sustained Akt signaling and inhibited by rapamycin. Cancer cell. 2006;10(2):159–70.

46. Luo X, Yang S, Liang J, Zhai Y, Shen M, Sun J, et al. Choroidal pericytes promote subretinal fibrosis after experimental photocoagulation. Dis Models Mechanisms. 2018;11(4).

47. Daniel E, Toth CA, Grunwald JE, Jaffe GJ, Martin DF, Fine SL, et al. Risk of scar in the comparison of age-related macular degeneration treatments trials. Ophthalmology. 2014;121(3):656–66.

48. Nguyen QD, Merrill PT, Sepah YJ, Ibrahim MA, Banker A, Leonardi A, et al. Intravitreal Sirolimus for the Treatment of Noninfectious Uveitis: Evolution through Preclinical and Clinical Studies. Ophthalmology. 2018;125(2):1984–93.

Publisher’s Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.